These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 20677260

  • 1. Focal nodular hyperplasia: central scar enhancement pattern using Gadoxetate Disodium.
    Karam AR, Shankar S, Surapaneni P, Kim YH, Hussain S.
    J Magn Reson Imaging; 2010 Aug; 32(2):341-4. PubMed ID: 20677260
    [Abstract] [Full Text] [Related]

  • 2. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
    Gupta RT, Iseman CM, Leyendecker JR, Shyknevsky I, Merkle EM, Taouli B.
    AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
    [Abstract] [Full Text] [Related]

  • 3. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI.
    Purysko AS, Remer EM, Coppa CP, Obuchowski NA, Schneider E, Veniero JC.
    AJR Am J Roentgenol; 2012 Jan; 198(1):115-23. PubMed ID: 22194486
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium.
    Bieze M, van den Esschert JW, Nio CY, Verheij J, Reitsma JB, Terpstra V, van Gulik TM, Phoa SS.
    AJR Am J Roentgenol; 2012 Jul; 199(1):26-34. PubMed ID: 22733890
    [Abstract] [Full Text] [Related]

  • 5. Focal nodular hyperplasia: a weight-based, intraindividual comparison of gadobenate dimeglumine and gadoxetate disodium-enhanced MRI.
    Taibbi A, Brancatelli G, Matranga D, Midiri M, Lagalla R, Bartolotta TV.
    Diagn Interv Radiol; 2019 Mar; 25(2):95-101. PubMed ID: 30860073
    [Abstract] [Full Text] [Related]

  • 6. Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: the role of laboratory factors.
    Chernyak V, Kim J, Rozenblit AM, Mazzoriol F, Ricci Z.
    J Magn Reson Imaging; 2011 Aug; 34(2):301-9. PubMed ID: 21608069
    [Abstract] [Full Text] [Related]

  • 7. MR findings of focal eosinophilic liver disease using gadoxetic acid.
    Lee J, Park CM, Kim KA, Lee CH, Choi JW.
    Magn Reson Imaging; 2010 Nov; 28(9):1327-34. PubMed ID: 20800984
    [Abstract] [Full Text] [Related]

  • 8. Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media.
    Marin D, Brancatelli G, Federle MP, Lagalla R, Catalano C, Passariello R, Midiri M, Vilgrain V.
    Clin Radiol; 2008 May; 63(5):577-85. PubMed ID: 18374723
    [Abstract] [Full Text] [Related]

  • 9. Hepatocyte-specific magnetic resonance imaging contrast agents.
    Fidler J, Hough D.
    Hepatology; 2011 Feb; 53(2):678-82. PubMed ID: 21274888
    [No Abstract] [Full Text] [Related]

  • 10. Magnetic resonance imaging findings of atypical focal nodular hyperplasia of the liver.
    Asbach P, Klessen C, Koch M, Hamm B, Taupitz M.
    Clin Imaging; 2007 Feb; 31(4):244-52. PubMed ID: 17599618
    [Abstract] [Full Text] [Related]

  • 11. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver.
    Ringe KI, Husarik DB, Sirlin CB, Merkle EM.
    AJR Am J Roentgenol; 2010 Jul; 195(1):13-28. PubMed ID: 20566794
    [Abstract] [Full Text] [Related]

  • 12. Hyperintense lesions on gadoxetate disodium-enhanced hepatobiliary phase imaging.
    Kim MJ, Rhee HJ, Jeong HT.
    AJR Am J Roentgenol; 2012 Nov; 199(5):W575-86. PubMed ID: 23096201
    [Abstract] [Full Text] [Related]

  • 13. Hepatic focal nodular hyperplasia: diagnosis by ultrafast Gd-DTPA enhanced FLASH MR.
    Urhahn R, Klose KC, Drobnitzky M.
    J Comput Assist Tomogr; 1991 Nov; 15(5):848-51. PubMed ID: 1885810
    [Abstract] [Full Text] [Related]

  • 14. Focal nodular hyperplasia of the liver: detection and characterization with plain and dynamic-enhanced MRI.
    Mortelé KJ, Praet M, Van Vlierberghe H, de Hemptinne B, Zou K, Ros PR.
    Abdom Imaging; 2002 Nov; 27(6):700-7. PubMed ID: 12395259
    [Abstract] [Full Text] [Related]

  • 15. Multiple focal nodular hyperplasia syndrome: diagnosis with dynamic, gadolinium-enhanced MRI.
    Finley AC, Hosey JR, Noone TC, Shackelford DM, Varadarajulu S.
    Magn Reson Imaging; 2005 Apr; 23(3):511-3. PubMed ID: 15862653
    [Abstract] [Full Text] [Related]

  • 16. Gadoxetate Disodium versus Gadoterate Meglumine: Quantitative Respiratory and Hemodynamic Metrics by Using Compressed-Sensing MRI.
    Glessgen CG, Moor M, Stieltjes B, Winkel DJ, Block TK, Merkle EM, Heye TJ, Boll DT.
    Radiology; 2019 Nov; 293(2):317-326. PubMed ID: 31549944
    [No Abstract] [Full Text] [Related]

  • 17. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver.
    Cruite I, Schroeder M, Merkle EM, Sirlin CB.
    AJR Am J Roentgenol; 2010 Jul; 195(1):29-41. PubMed ID: 20566795
    [Abstract] [Full Text] [Related]

  • 18. [The dynamic magnetic resonance study of focal liver lesions by FLASH sequences with bolus intravenous gadolinium-DTPA].
    Olivetti L, Grazioli L, Maroldi R, Matricardi L, Milanesio L.
    Radiol Med; 1992 Apr; 83(4):353-60. PubMed ID: 1318558
    [Abstract] [Full Text] [Related]

  • 19. Imaging of focal liver lesions: the 90 %-rule.
    Mostbeck G.
    Ultraschall Med; 2010 Dec; 31(6):545-7. PubMed ID: 21117006
    [No Abstract] [Full Text] [Related]

  • 20. [Differentiation of focal liver lesions using contrast-enhanced MRT].
    Heintz P, Ehrenheim C.
    Rofo; 1989 Mar; 150(3):297-306. PubMed ID: 2538880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.